Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 06, 2016 08:00 ET | Source: SteadyMed Therapeutics

Cardiome and SteadyMed Announce Decision for Centralized Review of Trevyent® by the European Medicines Agency

VANCOUVER, British Columbia and SAN RAMON, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Cardiome Pharma Corp. (Nasdaq:CRME), (TSX:COM) and SteadyMed Ltd. (Nasdaq:STDY), today announced that the...
January 05, 2016 07:30 ET | Source: SteadyMed Therapeutics

SteadyMed Receives Orphan Drug Designation for Trevyent for the Treatment of Pulmonary Arterial Hypertension

SAN RAMON, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value...
December 07, 2015 07:00 ET | Source: SteadyMed Therapeutics

SteadyMed Demonstrates Potential for Reduced Infusion Site Sensitivity Associated With Trevyent Compared to Remodulin

SAN RAMON, Calif., Dec. 7, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases...
November 12, 2015 16:05 ET | Source: SteadyMed Therapeutics

SteadyMed Reports Recent Developments and Third Quarter 2015 Financial Results

SAN RAMON, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value...
November 05, 2015 07:30 ET | Source: SteadyMed Therapeutics

SteadyMed to Report Recent Developments and Third Quarter 2015 Financial Results

SAN RAMON, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases...
October 28, 2015 07:30 ET | Source: SteadyMed Therapeutics

SteadyMed Announces Positive Clinical Study Results in Support of SMT-201 for the Treatment of Post Surgical Pain in the Home Setting

SAN RAMON, Calif., Oct. 28, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value...
October 21, 2015 07:00 ET | Source: SteadyMed Therapeutics

SteadyMed Files Inter Partes Review to Invalidate United Therapeutics Patent

SAN RAMON, Calif., Oct. 21, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value...
September 02, 2015 07:30 ET | Source: SteadyMed Therapeutics

SteadyMed to Participate in Upcoming Investor Conferences

SAN RAMON, Calif., Sept. 2, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value...
August 13, 2015 16:05 ET | Source: SteadyMed Therapeutics

SteadyMed Provides Insights on Recent Corporate Developments and Reports Second Quarter 2015 Financial Results

SAN RAMON, Calif., Aug. 13, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (NASDAQ:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value...
August 06, 2015 07:30 ET | Source: SteadyMed Therapeutics

SteadyMed to Provide Insights on Recent Corporate Developments and Report Second Quarter 2015 Financial Results

SAN RAMON, Calif., Aug. 6, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases...

Next Page keyboard_arrow_right